Stage II melanoma in the West of Scotland, 1976–1985: prognostic factors for survival. Eur J Cancer 1991;27:870–6.Tillman DM, Aitchison T, Watt DC et al. Stage II melanoma in the west of Scotland. 1976±85: prognostic factors for survival. Eur J Cancer 1991; 27: 870±6....
±16.6% for DAV-IFN-β therapy and 44.4±16.6% for non-use (0.67; 95% CI, 0.18–2.50; P = 0.55).Conclusions DAV-IFN-β therapy brought no significant improvement in either disease-free survival rates or melanoma-specific survival rates of patients with stage II or III cutaneous melanoma....
Analysis of survival and disease control in stage I melanoma of the head and neck. Am J Surg 1976;132:484-491.Ames FC, Sugerbaker EU, Ballantyne AJ (1976) Analysis of survival and disease control in stage I melanoma of the head and neck. Am J Surg 120:425...
Among 5575 patients with melanoma seen during the past 20 years, complete data on microstaging by both Clark and Breslow methods were available for 3323 patients. The 5-year survival rates were as follows: Clark II, 95%; III, 81%; IV, 68%; V, 47%. The Breslow thicknesses were as ...
Conclusions: This study demonstrates the survival differences across population subgroups as a result of a melanoma cancer diagnosis. Females experience better prognosis across age and stage at diagnosis; however, further investigation is necessary to better understand the mechanisms behind this difference....
Sex differences in presentation of cutaneous malignant melanoma and in survival from stage I disease. Cancer 1986;58:788-92.O'Doherty CJ, Prescott RJ, White H, McIntyre M, Hunter JA. Sex differences in presentation of cutaneous malignant melanoma in survival from stage I dis- ease. Can...
Distant metastasis-free survival with pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: The phase 3 KEYNOTE-716 study. Oral presentation at: the American Society for Clinical Oncology 2022 Annual Meeting; Chicago, Illinois; June 3-7, 2022.J Clin On...
Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer We found that a cohort of patients with lung cancer first treated in 1977 had higher six-month survival rates for the total group and for subgroups in each... AR Feinstein,DM Sosin,CK ...
Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific ... Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or ...
Moreover, the introduction of targeted therapy for LA-NSCLC patients with oncogenic driver mutations and systemic therapy such as immunotherapy has improved response rates and survival [[10], [11]]. However, this may lead to an increase in the incidence of intracranial metastases as patients ...